Bifidobacterium longum Qingjun 19 and application thereof in improvement of helicobacter pylori infection

By inhibiting the colonization and reproduction of Helicobacter pylori by Bifidobacterium longum Bianquejun 19, reducing putrefactive fatty acids, and regulating the intestinal microecology, the problem of gastric mucosal damage after Helicobacter pylori infection in existing technologies has been solved, achieving a more comprehensive therapeutic effect.

CN121896133APending Publication Date: 2026-04-21北京和益源生物技术有限公司 +1
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
CN202610363228.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-24
Publication Date
2026-04-21

AI Technical Summary

Technical Problem

While existing antibiotics are effective in eliminating Helicobacter pylori infection, they cannot address the mucosal barrier damage and related symptoms caused by gastric mucosal fibrosis following Helicobacter pylori infection. Furthermore, current probiotic preparations have insufficient butyrate conversion efficiency in the intestine, failing to meet the rapid and high-dose metabolic demands, resulting in unsatisfactory treatment outcomes.

Method used

We provide a strain of Bifidobacterium longum, Bianquejun 19, which inhibits the colonization and reproduction of Helicobacter pylori, reduces the content of putrefactive fatty acids, regulates the intestinal microecological balance, and repairs gastric mucosal damage. Specifically, this includes the preparation of bacterial agents and metabolites, as well as the pharmaceutical composition.

Benefits of technology

Bifidobacterium longum Bianquejun 19 can significantly reduce the production of isobutyric acid and isovaleric acid, repair gastric mucosal fibrosis and intestinal mucosal barrier damage, improve digestive tract damage caused by Helicobacter pylori infection, and provide more comprehensive treatment effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN121896133A_ABST
    Figure CN121896133A_ABST
Patent Text Reader

Abstract

The invention relates to the field of microorganisms, and discloses bifidobacterium longum Qingjun 19 and application of the bifidobacterium longum Qingjun 19 in improvement of helicobacter pylori infection. The preservation number of the bifidobacterium longum Qingjun 19 provided by the invention is CGMCC No.34431, and the bifidobacterium longum Qingjun 19 has the effects of inhibiting colonization and reproduction of helicobacter pylori and also can regulate intestinal metabolism, so that the content of beneficial fatty acid in the intestinal tract is increased, and meanwhile, the content of rotten fatty acid is remarkably reduced. Besides, the bifidobacterium longum also has a tissue remodeling capability, can specifically reverse gastric mucosa fibrosis caused by helicobacter pylori infection, has a positive effect on repairing the intestinal mucosa barrier, and provides a new treatment approach and basis for solving the intestinal barrier and gastric mucosa structure damage caused by helicobacter pylori infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of microbiology, specifically to a strain of Bifidobacterium longum, Bianquejun 19, and its use in improving Helicobacter pylori infection. Background Technology

[0002] Helicobacter pylori (Hp) infection is a significant contributing factor to diseases and conditions such as chronic active gastritis, peptic ulcers, and even gastric cancer. Hp infection not only directly damages the gastric mucosa but also disrupts the normal physiological balance of the gastrointestinal axis, causing intestinal flora imbalance and an abnormal increase in branched-chain short-chain fatty acids (such as isobutyric acid) and other irritating metabolites of the digestive tract mucosa. Furthermore, Hp infection can cause irreversible fibrosis, promoting the progression of atrophic gastritis towards gastric cancer.

[0003] Currently, antibiotics are commonly used in clinical practice to treat infected patients by eradicating Helicobacter pylori. However, although this treatment method is effective in eradicating Helicobacter pylori, patients still experience recurrent gastrointestinal symptoms and persistent inflammation, and the overall treatment effect is still significantly insufficient.

[0004] Therefore, there is an urgent need to develop novel drug formulations that can be used to treat Helicobacter pylori infection-related diseases and relieve discomfort symptoms. Summary of the Invention

[0005] The purpose of this invention is to overcome the aforementioned problems in the prior art and provide a strain of *Bifidobacterium longum*, Bianquejun 19, and its use in improving *Helicobacter pylori* infection. The *Bifidobacterium longum* provided by this invention not only effectively inhibits the colonization and reproduction of *Helicobacter pylori*, but also has the effects of reducing the content of putrefactive fatty acids in the intestine and repairing gastrointestinal mucosal damage caused by *Helicobacter pylori* infection.

[0006] The first aspect of this invention provides a strain of Bifidobacterium longum subsp. ( Bifidobacterium longum subsp. longum The preservation number of this subspecies of Bifidobacterium longum is CGMCC No. 34431.

[0007] A second aspect of the present invention provides a microbial agent containing the *Bifidobacterium longum* subsp. *longum* and / or the metabolites of the *Bifidobacterium longum* subsp. *longum* described in the first aspect.

[0008] A third aspect of the present invention provides a pharmaceutical composition, wherein the active ingredient of the pharmaceutical composition comprises the *Bifidobacterium longum* subsp. *longum* described in the first aspect, or the bacterial agent described in the second aspect.

[0009] The fourth aspect of this invention provides the use of the *Bifidobacterium longum* subsp. *longum* described in the first aspect, or the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect, in the preparation of a medicament for the prevention and / or treatment of diseases or symptoms caused by *Helicobacter pylori* infection.

[0010] The fifth aspect of the present invention provides a method for inhibiting the reproduction of Helicobacter pylori in vitro, the method comprising contacting the Bifidobacterium longum subsp. longum described in the first aspect, or the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect with Helicobacter pylori cultured in vitro.

[0011] The sixth aspect of the present invention provides a method for inhibiting the colonization of Helicobacter pylori in an in vitro culture, the method comprising contacting the in vitro culture with the Bifidobacterium longum subsp. longum described in the first aspect, or the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect, thereby inhibiting the colonization of Helicobacter pylori in the in vitro culture.

[0012] The beneficial effects obtained by the present invention through the above technical solution include at least the following: (1) The Bifidobacterium longum provided by the present invention is isolated from human fecal samples and belongs to human probiotics. Therefore, it is easy to colonize in the body and exert its effects. When used as a probiotic product, it can have good in vivo stability.

[0013] (2) The Bifidobacterium longum provided by the present invention can inhibit the colonization and reproduction of Hp and has the potential to be used to prepare probiotic drugs or preparations for anti-Helicobacter pylori infection.

[0014] (3) The *Bifidobacterium longum* provided by this invention can regulate the metabolism of digestive tract cells, promote the increase of beneficial fatty acid content in the intestine, and significantly reduce the content of putrefactive fatty acids in the intestine (for example, experimental verification shows that, compared with the model group, the application of this strain can reduce the production of isobutyric acid by up to about 29% and isovaleric acid by 51%). Moreover, the *Bifidobacterium longum* and its metabolites provided by this invention exhibit tissue remodeling ability, and can specifically repair and improve gastrointestinal damage induced by *H. pylori* infection, such as gastric mucosal fibrosis and intestinal mucosal barrier damage, providing a solution to the problems that existing treatments cannot address. Attached Figure Description

[0015] Figure 1 This is a colony morphology diagram of Bianque Jun 19 obtained in Example 1.

[0016] Figure 2 This is a graph showing the in vitro inhibition results of different Bianquejun 19 strain preparations against Helicobacter pylori in Example 2.

[0017] Figure 3 These are cell morphology diagrams of the control group and the model group in the adhesion inhibition experiment of Example 4.

[0018] Figure 4 This is a cell morphology diagram of the Bianquejun 19 strain preparation group in the adhesion inhibition experiment of Example 4.

[0019] Figure 5 These are cell morphology diagrams of the control group and the model group in the invasion inhibition experiment of Example 4.

[0020] Figure 6 This is a cell morphology diagram of the Bianquejun 19 strain preparation group in the invasion inhibition experiment of Example 4.

[0021] Figure 7 This is a diagram showing the HE staining results of the gastric mucosa of mice treated with different strains of Bianquejun 19 in Example 5.

[0022] Figure 8 This is a graph showing the results of detecting the inflammatory infiltration area of ​​the gastric mucosa in mice treated with different Bianquejun 19 strain preparations in Example 5.

[0023] Figure 9 This is a diagram showing the Masson staining results of the gastric mucosa of mice treated with different strains of the Bianque Jun 19 strain in Example 5.

[0024] Figure 10 This is a graph showing the results of detecting the relative collagen area of ​​the gastric mucosa of mice treated with different Bianquejun 19 strain preparations in Example 5.

[0025] Biological Preservation The strain provided by this invention is classified as *Bifidobacterium longum* subsp. *longum*. Bifidobacterium longum subsp. longum It was deposited on May 6, 2025 at the China General Microbiological Culture Collection Center, located at No. 3, Courtyard 1, Beichen West Road, Chaoyang District, Beijing, with accession number CGMCC No. 34431. Detailed Implementation

[0026] The endpoints and any values ​​of the ranges disclosed herein are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of the various ranges, the endpoint values ​​of the various ranges and individual point values, and individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed herein.

[0027] Through long-term research, the inventors discovered that while commonly used clinical methods for treating Helicobacter pylori infection, such as the "quadruple therapy" of antibiotics, can effectively kill the bacteria, they only focus on the eradication of Hp and do not pay attention to the problems such as damage to the mucosal barrier caused by gastric mucosal tissue fibrosis after Hp infection. As a result, even after successfully eradicating Helicobacter pylori, patients still need to take further measures to treat and alleviate symptoms such as long-term stomach discomfort and recurrent inflammation.

[0028] After conducting in-depth research on numerous existing probiotic anti-Hp infection preparations, the inventors of this invention discovered that existing anti-Hp microbial preparations not only suffer from significant deficiencies in butyrate conversion efficiency, effective concentration, and generation rate in the intestine, but also cause an increase in putrefactive fatty acid content. Although they possess Hp-inhibiting efficacy, they cannot meet the rapid, high-dose metabolic demands required for intestinal mucosal repair under severe Hp infection conditions, resulting in unsatisfactory treatment effects similar to antibiotic therapy. Through long-term research and screening, the inventors of this invention accidentally obtained a strain of *Bifidobacterium longum* from the feces of long-lived elderly individuals that can simultaneously inhibit gastric mucosal fibrosis and increase beneficial fatty acids while decreasing putrefactive fatty acids, naming it *Bifidobacterium longum* 19. *Bifidobacterium longum* 19 not only increases beneficial fatty acids and reduces putrefactive fatty acids, but also inhibits the reproduction and colonization of *Helicobacter pylori* in the body, regulates the intestinal microecological balance, and repairs damaged gastric mucosal barriers, potentially providing a new treatment approach for combating Hp infection and improving related symptoms.

[0029] Based on the above findings, the first aspect of this invention provides a strain of Bifidobacterium longum subsp. ( Bifidobacterium longum subsp. longum The preservation number of this subspecies of Bifidobacterium longum is CGMCC No. 34431.

[0030] In this invention, "Bianquejun 19", "Bifidobacterium longum Bianquejun 19", and "(the present invention provided) Bifidobacterium longum (long subspecies)" have the same meaning, all referring to the long subspecies of Bifidobacterium longum with accession number CGMCC No. 34431. This strain belongs to a subspecies of Bifidobacterium longum, but for ease of description, it can be simply referred to as Bifidobacterium longum in this invention. Unless otherwise specified, "Bifidobacterium longum" in this invention also refers to the long subspecies of Bifidobacterium longum with accession number CGMCC No. 34431.

[0031] A second aspect of the present invention provides a microbial agent containing the *Bifidobacterium longum* and / or the metabolites of the *Bifidobacterium longum* described in the first aspect.

[0032] According to some specific embodiments of the present invention, the metabolites may include active substances produced by *Bifidobacterium longum* through fermentation, including intracellular metabolites and / or extracellular metabolites. Specific forms of the metabolites may include, but are not limited to, fermentation supernatant (mainly containing intracellular metabolites, obtained by centrifugation to remove bacterial cells after fermentation) and bacterial lysis supernatant (including intracellular metabolites and / or extracellular metabolites, obtained by centrifugation after bacterial fermentation and cell lysis, which can simultaneously enrich intracellularly released active ingredients and extracellularly secreted active substances). The metabolites can be obtained from the *Bifidobacterium longum* fermentation system using conventional processes such as centrifugation, filtration, concentration, and freeze-drying.

[0033] According to some specific embodiments of the present invention, the fermentation supernatant may further include the supernatant obtained by centrifuging to remove the bacterial cells after fermentation of the strain without pH adjustment, and / or the supernatant obtained by centrifuging to remove the bacterial cells after fermentation of the strain and further adjusting the pH to neutral (in this invention, it is referred to as "neutral supernatant", with a pH of 6.8-7.2, such as 6.8, 6.85, 6.9, 6.95, 7, 7.05, 7.1, 7.15, 7.2, or any value between the above values ​​or any range of any two values).

[0034] According to some specific embodiments of the present invention, the viable count of Bifidobacterium longum in the bacterial agent can be 10. 2 -10 10 CFU / mL. 10 2 -10 10 CFU / mL refers to a concentration of 10 effective viable Bifidobacterium longum in the bacterial agent. 2 -10 10 CFU / mL level, for example, 1×10 2 CFU / mL, 5×10 2 CFU / mL, 8×10 2 CFU / mL, 9.9×10 2 CFU / mL were all within 10 2 CFU / mL level. That is, in this invention, the effective viable count of Bifidobacterium longum in the bacterial agent is greater than or equal to 1 × 10⁻⁶. 2 CFU / mL to less than 1×10 11 CFU / mL.

[0035] For example, the viable count of Bifidobacterium longum in the bacterial agent can be 1 × 10⁻⁶. 2 CFU / mL, 5×10 2 CFU / mL, 9×10 2 CFU / mL, 1×10 3 CFU / mL, 5×10 3 CFU / mL, 9×103 CFU / mL、1×10 4 CFU / mL、5×10 4 CFU / mL、9×10 4 CFU / mL、1×10 5 CFU / mL、5×10 5 CFU / mL、9×10 5 CFU / mL、1×10 6 CFU / mL、5×10 6 CFU / mL、9×10 6 CFU / mL、1×10 7 CFU / mL、2×10 7 CFU / mL、3×10 7 CFU / mL、4×10 7 CFU / mL、5×10 7 CFU / mL、6×10 7 CFU / mL、7×10 7 CFU / mL、8×10 7 CFU / mL、9×10 7 CFU / mL、1×10 8 CFU / mL、2×10 8 CFU / mL、3×10 8 CFU / mL、4×10 8 CFU / mL、5×10 8 CFU / mL、6×10 8 CFU / mL、7×10 8 CFU / mL、8×10 8 CFU / mL、9×10 8 CFU / mL、1×10 9 CFU / mL、2×10 9 CFU / mL、3×10 9 CFU / mL、4×10 9 CFU / mL、5×10 9 CFU / mL、6×10 9 CFU / mL、7×10 9 CFU / mL、8×10 9 CFU / mL、9×10 9 CFU / mL、1×10 10 CFU / mL、5×10 10 CFU / mL、9×10 10 CFU / mL、9.9×10 10CFU / mL, or any value between the above values ​​or a range consisting of any two values.

[0036] According to some preferred embodiments of the present invention, the method for preparing the microbial agent or metabolite (or preparation containing the metabolite) may include at least one of the following: (1) Bacterial suspension: Bianque Jun 19 was inoculated into MRS liquid medium and cultured anaerobically at 35-39℃ until the logarithmic or stationary growth phase. The viable cell concentration of the fermentation broth was adjusted to 10. 7- 10 9 CFU / mL is sufficient; Alternatively, the fermentation broth can be filtered or centrifuged to collect the cells, and then resuspended in MRS medium to a viable cell concentration of 10⁻⁶. 7- 10 9 CFU / mL; (2) Supernatant: Bianque Jun 19 was inoculated into MRS liquid medium and cultured anaerobically at 35-39℃ until the logarithmic or stable growth phase. The cells were removed by filtration or centrifugation, and the remaining liquid was the supernatant. (3) Neutral supernatant: Adjust the pH of the supernatant obtained by preparation method (2) to 6.8-7.2; (4) Lysis supernatant: Bianquejun 19 was inoculated in MRS liquid medium and cultured anaerobically at 35-39℃ until the logarithmic or stable growth phase. The cells were lysed, and then centrifuged or filtered to remove cell fragments. The remaining liquid part is the lysis supernatant.

[0037] Preferably, the preparation methods (2)-(4) above may further include sterilizing the collected supernatant, neutral supernatant and lysed supernatant. Sterilization is preferably performed by filtration (e.g., using a 0.22 μm filter membrane).

[0038] According to some preferred embodiments of the present invention, in the above preparation method (4), the lysis of bacterial cells can be carried out by grinding and shaking with glass beads, preferably with a glass bead diameter of 0.05-0.15 mm and a shaking time of 25-35 s.

[0039] The Bifidobacterium longum and its metabolites provided by the present invention are active or effective against damage or effects caused by Helicobacter pylori infection. Based on the above findings, the third aspect of the present invention provides a pharmaceutical composition, wherein the active ingredient of the pharmaceutical composition includes the Bifidobacterium longum described in the first aspect or the bacterial agent described in the second aspect.

[0040] According to some preferred embodiments of the present invention, the pharmaceutical composition may further contain pharmaceutically acceptable excipients. Any excipient commonly used in pharmaceutical preparation in the art is suitable for the present invention, such as excipients, preservatives, stabilizers, buffers, etc.

[0041] According to some specific embodiments of the present invention, the pharmaceutical composition may be provided in any dosage form, including liquid, semi-solid, and solid.

[0042] According to some specific embodiments of the present invention, the formulation may be a liquid formulation or a solid formulation; specifically, the supernatant / lysis supernatant may be concentrated, lyophilized or spray-dried to form a dry powder; the bacterial suspension may be lyophilized in the presence of a protectant to form a live bacterial powder; the dry powder may be further prepared into solid formulations such as granules, pills, capsules, tablets, or formulated with a pharmaceutically acceptable carrier into ointments, gels, sprays or liquid formulations.

[0043] Through extensive research, the inventors discovered that the *Bifidobacterium longum* provided by this invention can prevent and / or treat diseases or symptoms caused by *Helicobacter pylori* infection by inhibiting the reproduction and / or colonization process of *Helicobacter pylori*. Specifically, the *Bifidobacterium longum* provided by this invention can not only directly inhibit the growth and reproduction of *Helicobacter pylori*, but also co-agglutinate with *Helicobacter pylori* that has not successfully colonized, thereby reducing its contact with tissue cells by encapsulating *Helicobacter pylori*, thus reducing its adhesion and colonization probability, and promoting its excretion with gastrointestinal contents; moreover, the *Bifidobacterium longum* provided by this invention can not only prevent *Helicobacter pylori* from colonizing by competitively occupying adhesion sites on the surface of tissue cells (competitive mode) when *Helicobacter pylori* has not yet successfully infected or colonized, but also displace *Helicobacter pylori* that has already adhered to / invaded tissue cells when tissue cells have been colonized (displacement mode), and preventively reduce the probability of *Helicobacter pylori* infection by pre-adhering to tissue cells (rejection mode), thus reducing the *Helicobacter pylori* load in the body in three ways.

[0044] Specifically, Bianquejun 19 can not only inhibit the adhesion of Helicobacter pylori to tissue cells and thus inhibit its colonization, but also inhibit its invasion of tissue cells. Adhesion refers to the process by which Helicobacter pylori binds to specific receptors on the surface of tissue cells, thereby attaching itself to the cell surface. Invasion refers to the process by which Helicobacter pylori, after adhering to the surface of tissue cells, breaks through surface barriers (such as cell membranes and mucosal layers) and enters the tissue cells or intercellular spaces, further establishing colonization and potentially causing cell damage.

[0045] Therefore, the discovery of Bianque Jun 19 provides a basis for the prevention and / or treatment of diseases or symptoms caused by Helicobacter pylori infection.

[0046] Based on this, the fourth aspect of the present invention provides the use of the Bifidobacterium longum described in the first aspect, or the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of a medicament for the prevention and / or treatment of diseases or symptoms caused by Helicobacter pylori infection.

[0047] According to some preferred embodiments of the present invention, the diseases or symptoms caused by Helicobacter pylori infection may include primary symptoms related to Helicobacter pylori infection, such as chronic atrophic gastritis, duodenal ulcer, and precancerous lesions of the stomach caused by Helicobacter pylori infection, or secondary symptoms that occur or are aggravated by long-term inflammatory stimulation or microecological metabolic disorders after Helicobacter pylori infection, such as chronic inflammation of the gastric mucosa and irritable bowel syndrome.

[0048] According to some preferred embodiments of the present invention, the disease or symptom caused by Helicobacter pylori infection may include damage to the digestive tract mucosa. The digestive tract may include the upper and / or lower digestive tract, for example, at least one of the oral cavity, pharynx, esophagus, stomach, small intestine (duodenum, jejunum, ileum), and large intestine (cecum, colon, and rectum). According to a preferred embodiment of the present invention, the digestive tract is at least one of the stomach, small intestine (duodenum, jejunum, ileum), and large intestine (cecum, colon, rectum), preferably the stomach (i.e., the digestive tract mucosa is the gastric mucosa).

[0049] According to some preferred embodiments of the present invention, the gastrointestinal mucosal injury includes inflammatory changes and / or fibrotic lesions (including fibrotic lesions caused by collagen deposition).

[0050] In further research, the inventors also found that the application of Bianque Jun 19 can improve intestinal metabolism, specifically by increasing the content of beneficial fatty acids (such as C2-C5 saturated straight-chain fatty acids) in the intestine and inhibiting the production of putrefactive fatty acids (such as C4-C5 saturated branched-chain fatty acids).

[0051] Based on this, according to some preferred embodiments of the present invention, the drug is used to increase the content of C2-C5 saturated straight-chain fatty acids in the intestine and / or decrease the content of C4-C5 saturated branched-chain fatty acids in the intestine.

[0052] Furthermore, the present invention also provides the use of the Bifidobacterium longum described in the first aspect, or the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect in the preparation of a medicament for increasing the content of C2-C5 saturated straight-chain fatty acids and / or decreasing the content of C4-C5 saturated branched-chain fatty acids in the intestine.

[0053] In this invention, C2-C5 saturated straight-chain short-chain fatty acids are fatty acids produced by the fermentation of dietary fiber (carbohydrates) in the intestine, and are referred to in the art as beneficial short-chain fatty acids. Exemplarily, C2-C5 saturated straight-chain short-chain fatty acids may include one or more of acetic acid, propionic acid, butyric acid, and valeric acid. In this invention, C4-C5 saturated branched-chain fatty acids are fatty acids produced by the fermentation of dietary fiber (carbohydrates) in the intestine, and are different from C2-C5 saturated straight-chain short-chain fatty acids, and are referred to in the art as putrefactive short-chain fatty acids. Exemplarily, C4-C5 branched-chain fatty acids may include isobutyric acid and / or isovaleric acid.

[0054] The fifth aspect of the present invention provides a method for inhibiting the reproduction of Helicobacter pylori in vitro, the method comprising contacting the Bifidobacterium longum described in the first aspect, or the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect with Helicobacter pylori cultured in vitro.

[0055] The sixth aspect of the present invention provides a method for inhibiting the colonization of Helicobacter pylori in an in vitro culture, the method comprising contacting the in vitro culture with the Bifidobacterium longum described in the first aspect, or the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect, thereby inhibiting the colonization of Helicobacter pylori in the in vitro culture.

[0056] According to some specific embodiments of the present invention, the in vitro culture may include cells or organoids. Any cell or organoid capable of maintaining growth or function in an artificially simulated biological environment and capable of being infected by Helicobacter pylori can be used to inhibit the colonization of Helicobacter pylori in the culture using the Bifidobacterium longum described in the first aspect, the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect.

[0057] Preferably, the in vitro culture is obtained by in vitro culture of cells or tissues derived from the digestive tract.

[0058] This invention further provides the application of the *Bifidobacterium longum* described in the first aspect, or the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect, in constructing in vitro and in vivo experimental models of *Helicobacter pylori* infection. Exemplarily, the *Bifidobacterium longum* (such as its cells and / or metabolites) provided by this invention can intervene in the infection process in organs or tissues infected with *Helicobacter pylori*. By regulating the intestinal fatty acid metabolism profile (promoting the restoration of short-chain fatty acid composition in a favorable direction) and promoting mucosal barrier repair, it enables the *Helicobacter pylori* infection model to present a stable and controllable pathological state. Simultaneously, it can be used as an intervention group reagent to evaluate the therapeutic effects of different regimens on *Helicobacter pylori* infection.

[0059] The present invention further provides a method for constructing an in vivo or in vitro experimental model of Helicobacter pylori infection, the method comprising contacting the Bifidobacterium longum (including its cells and / or metabolites) described in the first aspect, or the bacterial agent described in the second aspect, or the pharmaceutical composition described in the third aspect, with cells or tissues infected with Helicobacter pylori.

[0060] In some preferred embodiments, the experimental model is an in vitro model. That is, the cells or cell cultures infected with Helicobacter pylori are cultured in vitro (such as two-dimensional cell cultures, and three-dimensional cultures such as organoids).

[0061] In some preferred embodiments, the experimental model is an in vivo model. That is, the animals infected with Helicobacter pylori are experimental animals.

[0062] The method provided by the present invention applies the present invention's Bifidobacterium longum, bacterial agent, or pharmaceutical composition to the cells or cell cultures and experimental animals infected with Helicobacter pylori, simulating the state of cells, tissues, and organisms during the treatment and recovery period after infection. This method can be used for mechanism studies related to Helicobacter pylori infection and treatment, drug action mechanism studies, and can also be used as a positive control in the drug screening process.

[0063] The present invention will be described in detail below through embodiments. It should be understood that the following embodiments are only used to further explain and illustrate the content of the present invention by way of example, and are not intended to limit the present invention.

[0064] In the following examples, unless otherwise specified, all reagents and materials used were commercially available products purchased from reputable chemical or biological reagent / material suppliers, and all reagents were of analytical grade or met the purity requirements of the experiment.

[0065] Example 1 This embodiment illustrates the isolation, activation, identification, preservation, and preparation of various forms of Bifidobacterium longum strain 19.

[0066] Strain isolation, activation, and identification: The inventors isolated a bacterium from a fecal sample obtained from a centenarian in Bama County, Guangxi Zhuang Autonomous Region, and named it Bianquejun 19. (The text abruptly ends here.) Figure 1 As shown, Bianquejun 19 forms milky white (or grayish white), round, raised colonies on agar plates with a smooth, moist surface and neat edges. The colonies are small in diameter (pinpoint to medium size), opaque or translucent. After 16S rRNA gene PCR amplification and sequencing, followed by sequence alignment and phylogenetic analysis, molecular biology, and physiological and biochemical tests (such as acid and bile salt tolerance), Bianquejun 19 was confirmed as a subspecies of Bifidobacterium longum. Bifidobacterium longum subsp. longum ).

[0067] Preparation of bacterial suspension: Bianquejun 19 strain was inoculated into MRS liquid medium and anaerobically cultured at 37℃ until the logarithmic growth phase or stationary phase. The fermentation broth (viable cell concentration 1×10⁻⁶) was then vortexed and mixed. 8 After centrifuging at 12000g for 10 min at 4℃, the supernatant was discarded, and the bacterial cell pellet was collected. The bacterial cells were resuspended in sterile PBS, washed twice, and finally resuspended in sterile PBS to obtain a bacterial suspension (viable cell concentration of 1×10⁻⁶ CFU / mL). 8 (CFU / mL).

[0068] Preparation of supernatant: Bianquejun 19 strain was inoculated into MRS liquid medium and anaerobically cultured at 37℃ until the logarithmic growth phase or stationary phase. The fermentation broth (viable cell concentration 1×10⁻⁶) was then vortexed and mixed. 8 After centrifuging at 12000g for 10 min at 4℃, the precipitate was discarded, and the resulting liquid was filtered through a 0.22μm sterile filter membrane to obtain the supernatant.

[0069] Preparation of neutral supernatant: The pH of the supernatant was adjusted dropwise to 7±0.2 with sterile NaOH aqueous solution (concentration 1mol / L), and then filtered through a 0.22μm sterile filter membrane to obtain neutral supernatant.

[0070] Preparation of lysis supernatant: The bacterial suspension was shaken with 0.1 mm glass beads at 5000 rpm for 30 s, then centrifuged at 12000 g for 10 min at 4 °C. The collected supernatant was filtered through a 0.22 μm sterile filter membrane to obtain the lysis supernatant.

[0071] Example 2 This embodiment illustrates the in vitro inhibitory effect of Bifidobacterium longum Bianquejun 19 on Helicobacter pylori.

[0072] In this embodiment, the microaerophilic culture environment is formed by placing the culture in a sealed container and adding a 2.5L microaerophilic gas generating bag (purchased from Mitsubishi Corporation, Japan, gas ratio: oxygen 9±3% by volume, carbon dioxide 6±2% by volume, and the remainder nitrogen).

[0073] Activation process of Helicobacter pylori (Hp, ATCC43504): The frozen Hp culture was removed from -80℃ and thawed. 20 μL of the culture was spread onto a 2:1 (w / w) agar plate containing 10% fetal bovine serum (FBS). After inoculation, the plate was placed in a sealed container and incubated at 37℃ under a microaerophilic environment until typical small, translucent / grayish-white colonies appeared (approximately 3-5 days). Sterile PBS was added to the plate, and Hp was scraped off and evenly spread onto a fresh plate of the same formulation to obtain the first generation of activated Hp. The first generation of activated Hp was then inoculated onto freshly prepared solid culture medium of the same formulation and incubated until typical small, translucent / grayish-white colonies appeared (approximately 3-5 days), yielding the second generation of activated Helicobacter pylori. The concentration of Hp in the activated culture was adjusted to 1 × 10⁻⁶ using sterile PBS. 8 CFU / mL was plated onto fresh Columbia agar plates containing a selective antibiotic for Helicobacter pylori (Solepro, catalog number LA7471, 1 mL antibiotin / 100 mL culture medium). The plates were immediately placed in Oxford cups, and 100 μL each of the various forms of Bianquejun 19 bacterial strain preparations (supernatant, neutral supernatant, bacterial suspension, and lysis supernatant) prepared in Example 1 were added. The plates were then placed in a sealed container and incubated in a microaerophilic environment. After fixation at 4°C for 1 h, the plates were incubated at 37°C for 72 h. The diameter of the inhibition zone was measured, and the ratio of the area of ​​a single well in the inhibition zone to the area of ​​the culture dish (single-well area ratio) was calculated. Measurements were repeated three times. The results of the in vitro antibacterial experiment are as follows: Figure 2 As shown in the figure (the positions of the inhibition zones of different bacterial preparations are drawn with circles), the specific diameters of the inhibition zones and the percentage of the area per well are shown in Table 1.

[0074] Percentage of area per well (%) = Area of ​​inhibition zone of bacterial strain / Area of ​​petri dish × 100 Table 1

[0075] Note: In Table 1, different letters indicate that the differences between groups are statistically significant. p <0.05; the same letter indicates that the difference between groups is not statistically significant ( p >0.05).

[0076] The results showed that all forms of the Bianque Jun 19 strain preparations exhibited significant antibacterial activity, with the neutral supernatant showing the best performance. The amount of non-acid-dependent specific antibacterial factor secreted was characterized by the area of ​​the inhibition zone. The amount of non-acid-dependent specific antibacterial factor secreted in the neutral supernatant was about 107% higher than that in the lysed supernatant and about 28% higher than that in the supernatant. This means that the Bianque Jun 19 strain can exert antibacterial effects in different microenvironments of the gastric mucus layer: it can not only fight bacteria in the acidic gastric mucosa environment, but also in the neutral microenvironment of the gastric mucus layer (such as the side of the mucus layer close to the gastric mucosal epithelial cells). This further proves that even under non-acidic conditions, Bianque Jun 19 can effectively eliminate Helicobacter pylori.

[0077] In the Oxford Cup inhibition zone experiment, although the bacterial suspension showed no inhibition zone formation, this was mainly because the bacterial suspension was mainly composed of intact live bacterial cells, which had limited diffusion ability in the agar medium and could not fully contact Helicobacter pylori. The effect of Bifidobacterium longum Bianquejun 19 on inhibiting the reproduction of Helicobacter pylori still needs further experimental confirmation.

[0078] Example 3 This example illustrates the effect of Bifidobacterium longum Bianquejun 19 on the aggregation of Helicobacter pylori.

[0079] (1) Self-aggregation Bianquejun 19 or Hp bacterial suspension adjusted OD with PBS 600 =0.5±0.05 to obtain the test liquid, place it in a 37℃ static incubator, and measure the OD of the upper layer of the test liquid before incubation. 600 Absorbance value A0 and OD values ​​at different incubation times 600 Absorbance A t The self-agglomeration rate of Bianquejun 19 or Hp was calculated according to the following formula (I). The results of the self-agglomeration rate over time are shown in Table 2.

[0080] Self-agglomeration rate (%) = (A0 - A) t ) / A0×100 formula (I) (2) Coagulation The Bianquejun 19 bacterial suspension was mixed with an equal volume of Hp bacterial suspension to obtain a mixed bacterial suspension. The mixture was thoroughly shaken for 5 min and then incubated at 37℃. The OD values ​​of the initial supernatant of the test liquid and the Hp supernatant were measured. 600 Absorbance B x and B y and OD values ​​of mixed bacterial cultures at different times 600 Absorbance B t The coagulation rate of Bianquejun 19 and Hp was calculated according to the following formula (II). The results of the coagulation rate over time are shown in Table 2.

[0081] Coagulation rate (%) = (1-2B) t / (B) x +B y (II) × 100 Table 2

[0082] The results are shown in Table 2. Regarding autoagglutination, the autoagglutination rate of Bianque Jun 19 was higher than that of Helicobacter pylori, indicating that compared to Helicobacter pylori, Bianque Jun 19 bacteria have stronger intercellular aggregation ability, are more likely to form stable bacterial clusters, and thus adhere more easily to the digestive tract. They are less likely to be flushed out by peristalsis and digestive juices, allowing for better colonization of the intestines and prolonging their probiotic function. Regarding coagulation, the coagulation rate of Bianque Jun 19 increased significantly over time, reaching 24% at 4 hours, and from 4 hours onwards, its coagulation rate remained higher than that of Hp. This result indicates that Bianque Jun 19 possesses the surface characteristic of recognizing and binding to pathogenic bacteria. Under long-term coexistence conditions, the live Bianque Jun 19 bacteria can physically disrupt the dispersed state of Hp and form co-precipitates, which is the basis for the bacterial suspension group's physical repulsion mechanism to block Hp colonization. In summary, Bianquejun 19 can synergistically intervene in the adhesion and colonization process of Helicobacter pylori by forming stable bacterial clusters through self-agglutination and capturing and aggregating Helicobacter pylori through co-agglutination.

[0083] Example 4 This embodiment illustrates the inhibitory effect of Bifidobacterium longum Bianquejun 19 on the reproduction and colonization of Helicobacter pylori in vitro.

[0084] GES-1 gastric epithelial cells (purchased from Wuhan Pronosai Life Science Technology Co., Ltd., hereinafter referred to as gastric epithelial cells) were used at a concentration of 1×10⁻⁶. 4 Cells were seeded at a density of 1:1 in 96-well plates and cultured at 37°C and 5% CO2 until 80-90% confluence. The culture medium was then discarded, and the cells were washed twice with serum-free Dalberg modified Eagle medium (DMEM). Subsequently, the cells were treated in three different modes (treatment groups, with two parallel experiments per treatment group), under the following culture conditions: 37°C and 5% CO2 gas conditions: (1) Competition mode: 100 μL of Hp bacterial culture (MOI=100) and 100 μL of different strains of Bianquejun 19 were added to the samples at the same time and cultured for 4 hours. (2) Exclusion mode: First, add 100 μL of different forms of Bianquejun 19 bacterial strain preparations, incubate for 2 hours, wash with PBS, and then add 100 μL of Hp bacterial solution for co-culture for 2 hours. (3) Replacement mode: First, add 100 μL of Hp bacterial solution and incubate for 2 hours. After washing with PBS, add 100 μL of different forms of Bianquejun 19 bacterial strain preparation and continue incubation for 2 hours.

[0085] In each of the modes (1)-(3), a control group without Hp bacterial solution and Bianquejun 19 and a model group with only Hp were set up.

[0086] After culture, a cell adhesion inhibition experiment was performed, with one set of parallel experiments used to test the adhesion inhibition rate. Another set of parallel experiments underwent gentamicin post-treatment to perform a cell invasion inhibition experiment, followed by testing the invasion inhibition rate.

[0087] Post-treatment with gentamicin: Wash cells three times with PBS to remove suspended bacteria, add culture medium containing 100 μg / mL gentamicin, and incubate at 37°C for 2 hours to specifically kill extracellular bacteria that have not invaded, and use this to test the invasion inhibition rate.

[0088] Adhesion / invasion inhibition rate test procedure: After each reaction mode was completed, the culture medium was aspirated, and the cells were gently washed 5 times with PBS to thoroughly remove unadhesed bacteria. 40 g / L paraformaldehyde was added for fixation at room temperature for 15 minutes, and the cells were then air-dried. Next, 100 μL of 0.1 g / L crystal violet solution was added to each well for staining at room temperature for 15 minutes. After washing away any excess stain and air-drying, 33% (v / v) glacial acetic acid was added and the cells were shaken for 10 minutes (until completely dissolved). The absorbance (OD) values ​​at 550 nm of the model group and the treatment group were measured using a microplate reader. 模型组 and OD 处理组 .

[0089] Adhesion / Invasion Inhibition Rate (%) = [(OD 模型组 –OD 处理组 ) / OD 模型组 ]×100 For cell adhesion inhibition experiments: Cell morphology diagrams of the control group and the model group are shown below. Figure 3 As shown, where, Figure 3 (A) is a morphological diagram of the control group cells, which show a stark contrast to the physiological characteristics of maintaining a regular polygonal shape, sharp boundaries, and uniformly translucent light pink cytoplasm. Figure 3 (B) is a cell morphology diagram of the model group. The gastric mucosal cells in the diagram show the most specific severe cytotoxic reaction, manifested as diffuse cytoplasmic vacuolation (indicated by orange arrows), serrated deformation of cell edges, and a significant increase in cytoplasmic eosinophilia (from light pink to dark red), suggesting toxin-mediated endometrial system disorder and protein denaturation. Figure 4 Images (A)-(C) show the cell morphology of the supernatant, bacterial suspension, and lysate supernatant in the competitive mode, respectively. The blue arrows indicate the Bianquejun 19 cells (which are slender rod-shaped). Figure 4(B) The physical invasion of the pathogen was clearly demonstrated. The specific adhesion of Bianquejun 19 (blue arrow) and the aggregation of bacteria around the cell were clearly visible, resulting in a rough cell membrane surface, blurred outline and turbid granular texture of cytoplasm. Figure 4 (A) and Figure 4 (C) The gastric mucosal cells showed shrinkage, irregular edges, and granular degeneration of the cytoplasm, with some nuclei exhibiting signs of pyknosis and deep staining, suggesting activation of apoptosis or necrosis pathways. In summary, each experimental group successfully reproduced a series of distinct cytopathic effects, from bacterial surface colonization and toxin-induced vacuolation to organelle disintegration and necrosis, strongly confirming the significant toxicity of this pathogenic factor in disrupting the cytoskeleton and metabolic function.

[0090] For the invasion inhibition experiment: Cell morphology diagrams of the control group and the model group are shown below. Figure 5 As shown. Among them, Figure 5 (A) is a cell morphology diagram of the control group, showing the basic morphology of gastric epithelial cells in the absence of Helicobacter pylori. Figure 5 (B) is a cell morphology diagram of the model group. The gastric epithelial cells show typical characteristics of severe infection: a large number of dark red Helicobacter pylori are visible on the edge and surface of the cell membrane (presenting dense dark bacterial clumps). Some cells show stress-induced pathological changes such as nuclear condensation, deep cytoplasm staining and cell aggregation, which confirms that the pathogen's adhesion and invasion of the host cells caused significant morphological damage.

[0091] Figure 6 (A)-(C) are, in order, diagrams of cell morphology in the supernatant, bacterial suspension, and lysis supernatant treatments in the competition mode. Figure 6 As shown, the experimental groups treated with different forms of Bianque Jun 19 bacterial strain preparations all exhibited significant protective effects against invasion: Figure 6 (A) and Figure 6 In (C), the morphology of gastric epithelial cells and Figure 5 (A) Highly similar cells, with relaxed cell morphology, normal nuclear staining, clear cytoplasm, and a clear field of view, with almost no colonization or internalization of pathogens observed. This indicates that the extracellular metabolites and intracellular active components of Bianquejun 19 can effectively block Helicobacter pylori from entering gastric epithelial cells, thereby maintaining the structural integrity of the cells. Figure 6In (B), under the microscope, clearly visible elongated rod-shaped Bianquejun 19 bacteria are distributed around the cells, coexisting with a small number of scattered punctate Helicobacter pylori. This result confirms that the live Bianquejun 19 bacteria physically block the binding of pathogens to host cell receptors through steric hindrance and competitive repulsion mechanisms, thereby significantly reducing the risk of pathogen invasion. However, although the bacterial suspension group may have a steric hindrance effect, from the perspective of the visual clearance of pathogens, its non-cellular contact chemical inhibition (i.e., metabolites and intracellular substances) is more superior.

[0092] Table 3

[0093] Note: In Table 3, different letters indicate that the differences between groups are statistically significant. p <0.05; the same letter indicates that the difference between groups is not statistically significant ( p >0.05).

[0094] In the adhesion experiment, the supernatant of Bianquejun 19 showed the highest adhesion inhibition rate (53.99%) in the "displacement mode," significantly better than its performance in the exclusion or competition modes (35.25% and 34.88%, respectively), confirming that the secretory active metabolites of this strain can effectively eliminate colonized pathogens. In contrast, the bacterial suspension performed best in the "exclusion mode" (42.12%), indicating that it mainly exerts its preventive effect by pre-occupying adhesion sites to form steric hindrance, rather than directly competing with pathogens.

[0095] In the invasion experiment, the suspension and intracellular lysate of *H. pylori* strain Bianquejun 19 exhibited significant protective effects. The bacterial suspension showed the highest invasion inhibition rate (73.57%) in the "competitive mode" and reached 69.67% in the "rejection mode," both significantly better than the "displacement mode" (47.31%) in the same group. This trend indicates that this strain mainly functions through a "competitive rejection" mechanism: by occupying binding sites on the host cell surface with high affinity, it forms a physical barrier, thereby blocking *H. pylori* recognition and endocytosis of host cells at the source, effectively reducing the risk of intracellular infection. This suggests that this function mainly depends on the mediation of bacterial surface structures or intracellular specific factors.

[0096] Combined with microscopic morphological observation and quantitative analysis of adhesion inhibition rate, it was shown that Bianquejun 19 has excellent anti-Helicobacter pylori invasion activity. Its live bacteria exert a defensive effect through competitive exclusion, while its metabolites and lysates exert a protective effect by blocking the internalization pathway. Both can significantly reduce the cellular pathological damage caused by Helicobacter pylori infection.

[0097] Example 5 This embodiment illustrates the effects of Bifidobacterium longum Bianquejun 19 on the colonization of Helicobacter pylori, fatty acid metabolism, and digestive tract tissue characteristics in vivo.

[0098] Eight-week-old male SPF-grade Balb / C mice (n=10 per group, purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., catalog number 8000002242) were selected and acclimatized for 7 days before model initiation. Days 8-21 were the infection modeling period. Except for the control group, the other mice were fasted for 24 hours and then administered 0.2 mL of NaHCO3 solution (0.2 mol / L) by gavage to neutralize gastric acid. Thirty minutes later, they were administered 0.2 mL of *Helicobacter pylori* suspension (concentration 5 × 10⁻⁶). 8 The fasting and gavage treatments were cycled every two days (i.e., one day without fasting, one day with gavage, and one treatment cycle was two days), lasting for two weeks. Days 22-28 were the Hp colonization period, during which mice ate water and feed normally without any additional treatment. Days 29-70 were the intervention treatment period, during which the model mice were randomly divided into the model group, the mixed antibiotic group (the mixed antibiotic was a compound solution of 0.025 μg / mL omeprazole, 0.125 μg / mL amoxicillin and 0.5 μg / mL metronidazole), the supernatant group, the bacterial suspension group, and the lysis supernatant group (the dosage of mixed antibiotic, supernatant, bacterial suspension and lysis supernatant were all 0.2 mL / mouse / day), and they ate water and feed normally.

[0099] 1. Detection of short-chain fatty acids (SCFAs) in colon contents The contents of SCFAs such as acetic acid, propionic acid, and butyric acid in colonic contents were determined by gas chromatography-mass spectrometry (GC-MS). The results are shown in Table 4, with units of μmol / g (i.e., the molar content of the corresponding fatty acids per gram of colonic contents).

[0100] Table 4

[0101] Note: In Table 4, different letters indicate that the differences between groups are statistically significant. p <0.05; the same letter indicates that the difference between groups is not statistically significant ( p >0.05).

[0102] Results from the model and control groups showed that *H. pylori* infection led to fatty acid metabolism disorders in the mouse gut, specifically a deficiency of beneficial fatty acids (acetic acid and butyric acid) and an abnormal accumulation of putrefactive fatty acids (isovaleric acid and isobutyric acid). Specifically, the isobutyric acid level in the model group was significantly increased to approximately 45 μmol / g, significantly higher than the approximately 30 μmol / g in the control group, confirming that the modeling treatment successfully induced enhanced putrefactive metabolism in the gut. This metabolic disorder was significantly reversed after intervention with Bianquejun 19 (especially the bacterial suspension and supernatant). Among the various interventions, the lysate supernatant group showed the best improvement, with isobutyric acid levels dropping sharply to approximately 33 μmol / g. This indicates a significant difference from the model group and a complete recovery to the healthy levels of the control group. In contrast, while the mixed antibiotic group, supernatant group, and bacterial suspension group also showed a decreasing trend in values, there was no significant difference from the model group. This means that these groups have not yet achieved the complete statistical recovery seen in the lysate supernatant group. This result suggests that the lysis supernatant may contain a more crucial active ingredient in inhibiting isovaleric acid production. Furthermore, the isovaleric acid content in the model group was abnormally high, reaching approximately 370 μmol / g, significantly higher than the 180 μmol / g in the control group, indicating that the modeling treatment exacerbated harmful putrefactive metabolism in the intestine, and all intervention groups showed a significant reversal effect on isovaleric acid accumulation. Compared with the model group, the isovaleric acid content in the supernatant group, bacterial suspension group, and lysis supernatant group was significantly decreased. This result strongly confirms that Bianque Jun 19 can effectively improve the intestinal microenvironment by inhibiting the metabolic activity of putrefactive bacteria, reshaping the intestinal metabolic profile from a pathological "high putrefactive state" to a healthy physiological state. This result indicates that this strain can not only directly inhibit the reproduction and colonization of *Helicobacter pylori*, but also improve the intestinal microecological imbalance caused by infection by reshaping the intestinal metabolic environment, promoting acid production by beneficial bacteria, and inhibiting putrefactive metabolism.

[0103] (2) Examination of digestive tract tissue characteristics Gastric tissue acquisition and fixation process: The stomach is longitudinally cut along the greater curvature. The gastric cavity is gently rinsed with PBS to remove chyme / mucus, avoiding vigorous scraping of the mucosa. The gastric tissue is laid flat on a sterile operating table and divided into two parts longitudinally (cardia-pyloric axis): one half is used for fixation, laid flat with the mucosal side facing up and then fixed in 40 g / L paraformaldehyde; the other half is used for cryopreservation, after aspirating the surface liquid, it is placed in a pre-cryopreservation tube, flash-frozen in liquid nitrogen, and then transferred to... Store at 80℃ for subsequent molecular or metabolic-related assays. After fixation, gastric tissue was dehydrated with graded ethanol, cleared with xylene, embedded in paraffin, and then prepared into 4-5 μm serial sections.

[0104] HE staining: The sections were routinely stained with hematoxylin and eosin (H&E) and observed under a light microscope to observe the infiltration of inflammatory cells, epithelial shedding, and structural integrity of the gastric mucosa.

[0105] Masson staining: Sections were treated with Masson's trichrome staining method, and collagen fiber deposition was observed under a microscope (collagen fibers appear blue, and muscle fibers appear red). ImageJ software was used for semi-quantitative analysis of the positive area of ​​collagen fibers to assess the degree of gastric mucosal fibrosis.

[0106] The results and analysis of the above tests are as follows: The results of HE staining and Masson staining are as follows: Figure 7 and Figure 9 As shown, where, Figure 7 and Figure 9 In the diagram, A, B, C, D, E, and F represent the staining results of the control group, model group, mixed antibiotic group, supernatant group, bacterial suspension group, and lysis supernatant group, respectively.

[0107] ImageJ was used to perform color separation on HE images to obtain the Hematoxylin channel. Within the tissue region of interest (ROI), nuclear-staining positive areas were segmented using a threshold and their areas were measured. The inflammatory infiltration area was calculated using the following formula, and the results are as follows: Figure 8 As shown in Table 5; Inflammatory infiltration area (%) = Nuclear-staining positive area / Tissue area × 100% The area of ​​collagen-positive regions within the tissue ROI of the Masson image was obtained by color thresholding, and the relative collagen area (CVF) was calculated using the following formula. The results are as follows. Figure 10 As shown in Table 5.

[0108] Relative collagen area (%) = Collagen-positive area / Tissue area × 100% The test results are as follows: (1) Results of HE staining of cell morphology Figure 7 (A) shows that the gastric mucosa of the control group was intact, with continuous surface epithelium, regularly arranged and dense glands, and clear structures of the mucosa, muscularis mucosae, and submucosa. No obvious inflammatory cell aggregation or only mild infiltration was observed in the lamina propria, suggesting that the tissue was in a relatively normal state.

[0109] Figure 7 (B) shows that the gastric mucosa in the model group exhibited significant pathological damage, characterized by mucosal thickening accompanied by focal erosion or surface epithelial abrasion, disordered gland arrangement, and gland rupture and collapse in some areas. Significant inflammatory cell infiltration was observed in the lamina propria, and obvious edema and vasodilation were visible in the submucosa, suggesting a severe acute inflammatory response. Mucosal shedding and gland exposure may have provided more adhesion sites for Helicobacter pylori, indicating that the model group was in a highly adhesive and persistent infection state.

[0110] Figure 7 (C) shows that, compared with the model group, the gastric mucosal damage in the mixed antibiotic group was significantly reduced, the continuity of the surface epithelium was partially restored, the area of ​​mucosal shedding was significantly reduced, and the glandular structure was more regular. The infiltration of inflammatory cells in the lamina propria was significantly reduced, and the inflammatory activity was significantly decreased; mild chronic inflammatory changes were visible in the submucosa, which has a certain protective effect on the mucosal barrier.

[0111] Figure 7 (D) shows that the gastric mucosal structure in the supernatant group was significantly improved compared to the model group. Surface epithelial continuity was restored, the extent of mucosal sloughing / erosion was reduced, and glandular arrangement became more regular. The degree of chronic inflammatory cell infiltration in the lamina propria was reduced, neutrophil infiltration was significantly decreased, and inflammatory activity was significantly suppressed; submucosal edema was significantly alleviated compared to the model group. The restoration of the mucosal barrier structure helps reduce direct contact between Helicobacter pylori and epithelial cells, thereby inhibiting its adhesion process.

[0112] Figure 7 (E) shows that gastric mucosal damage was further alleviated in the bacterial suspension group, with the mucosal structure remaining largely intact (although mucosal thickening was more pronounced). The surface epithelium showed good continuity, with almost no obvious mucosal shedding or gland exposure; the glands were regularly arranged and clearly defined. Inflammatory cell infiltration in the lamina propria was further reduced compared to the supernatant group, with only mild chronic inflammation observed. The inflammatory activity score was significantly lower, and submucosal edema had largely disappeared, although some degree of inflammatory cell infiltration was still visible. The intact mucosal structure and stable epithelial barrier significantly reduced the adhesion opportunity of Helicobacter pylori, suggesting that live bacteria have an advantage in competitive occupancy and adhesion inhibition.

[0113] Figure 7 (F) shows that the gastric mucosal structure in the lysate group was more intact overall, with a more continuous surface epithelium and relatively regular glandular arrangement. Inflammatory cell infiltration in the lamina propria was significantly reduced compared to the model group, and the overall morphology was similar to the control group, suggesting that the lysate supernatant has a significant protective effect in alleviating infection-related mucosal damage. Only a small number of scattered chronic inflammatory cells remained in the lamina propria, indicating that this treatment has the best protective and repairing effect on gastric mucosal damage, and the lysate products can significantly repair the mucosal barrier, minimizing the adhesion sites available to Helicobacter pylori.

[0114] Furthermore, inflammatory infiltration focuses on the intensity of the immune response, while tissue structural integrity focuses on the restoration of physical barriers and cell morphology. Different interventions may preferentially act on the inflammatory response or the tissue repair process. Inflammation resolution and tissue repair occur in stages, and observation at a single time point may not capture the comprehensive dynamic changes. Based on the description results of the HE images, and considering the overall tissue morphology, the order from mild to severe is as follows: control group, lysate supernatant group, mixed antibiotic group, supernatant group, bacterial suspension group, and model group.

[0115] (2) Masson staining results of cell morphology Figure 9 (A) shows that the gastric mucosa and submucosa of the control group are clearly structured, with thin and continuous collagen fibers mainly located in the submucosa and around blood vessels. The blue staining area is small and evenly distributed, and no abnormal collagen deposition or fibrosis changes are observed, suggesting that the gastric tissue is in a normal structural state.

[0116] Figure 9 (B) shows a significant increase in blue-stained collagen fibers in the gastric tissue of the model group, mainly concentrated in the submucosa and around the injured area, extending into the mucosa. Locally, collagen fibers were observed to be deposited in bundles and sheets, with disordered tissue layer structure, suggesting significant collagen deposition and early fibrosis following acute injury. The abnormal collagen proliferation highly overlapped with areas of mucosal shedding and inflammatory infiltration, suggesting that persistent inflammation and Helicobacter pylori adhesion may induce early fibrosis, hindering mucosal structural recovery.

[0117] Figure 9 (C) shows that, compared with the model group, the deposition of collagen fibers in the gastric tissue of the mixed antibiotic group was significantly reduced, the blue staining area was significantly reduced, the mucosa and submucosa structure was more intact, and the distribution of collagen fibers tended to be more regular. However, mild collagen hyperplasia was still visible in some areas, indicating that the degree of fibrosis was alleviated to a certain extent.

[0118] Figure 9 (D) shows that although acute inflammation was alleviated in the gastric tissue of the supernatant group, the abnormal deposition of collagen fibers was not completely improved, and obvious blue-stained areas were still visible in the submucosa, with irregular fiber arrangement. This suggests that although extracellular metabolites alone can combat acute inflammation, their efficacy in reversing deep pathological fibrosis is limited.

[0119] Figure 9 (E) shows that the blue-stained collagen fibers in the gastric tissue of the bacterial suspension group were further reduced, and the collagen distribution pattern was close to that of the normal control group. Only a small amount of physiological collagen was visible in the blood vessels and submucosa, and no obvious fibrosis foci were observed, suggesting that live bacteria intervention has a more significant effect in alleviating abnormal collagen deposition.

[0120] Figure 9 (F) shows that the deposition of collagen fibers and the blue staining area in the gastric tissue of the lysate supernatant group were significantly lower than those in the model group and other treatment groups. The collagen fibers were arranged in a fine and regular manner, and the mucosa and submucosa were intact. The overall morphology was highly similar to that of the control group, suggesting that this treatment was the most effective in inhibiting gastric tissue fibrosis and promoting structural repair.

[0121] (3) Results of inflammatory infiltration and relative collagen area Table 5

[0122] Note: In Table 5, different letters indicate that the differences between groups are statistically significant. p <0.05; the same letter indicates that the difference between groups is not statistically significant ( p >0.05).

[0123] Figure 8 The results of the inflammatory infiltration area in Table 5 show that the inflammatory cell infiltration area in the model group was significantly higher than that in the normal control group. After intervention, the inflammatory area in each group was significantly reduced, with the supernatant group showing the best performance, significantly better than the bacterial suspension group and the lysate supernatant group.

[0124] Figure 10 The relative collagen area results in Table 5 show that the relative collagen area of ​​the gastric mucosa in the model group mice was significantly higher than that in the normal control group, indicating that Helicobacter pylori infection induced severe pathological fibrosis. The intervention results showed that the lysate supernatant group and the bacterial suspension group exhibited the best efficacy in anti-fibrosis, with their collagen area decreasing to a level not significantly different from the mixed antibiotic group, successfully restoring the fibrosis level to near-normal physiological conditions. It can be seen that the core active substances of Bianquejun 19 in reversing gastric mucosal fibrosis and regulating extracellular matrix remodeling are mainly stored intracellularly or dependent on bacterial cell structures, which forms a distinct mechanistic complement to its anti-inflammatory effect, which mainly relies on secretions.

[0125] Based on the combined results of inflammatory infiltration, relative collagen area, and HE and Masson staining, it can be concluded that Helicobacter pylori infection leads to severe gastric mucosal shedding, gland exposure, and enhanced inflammatory response, thus significantly increasing the chances of its adhesion and persistent colonization. Different forms of bacterial preparations can effectively restore the integrity of the gastric mucosal barrier and reduce the number of adhesion sites available to Helicobacter pylori by repairing mucosal structure, reducing inflammatory response, and decreasing abnormal collagen deposition. Among these, bacterial suspension and lysis supernatant treatment showed more significant effects, suggesting their important role in inhibiting Helicobacter pylori adhesion and blocking infection progression. It is noteworthy that although the mixed antibiotic group reduced acute inflammation and submucosal edema to some extent by killing the pathogen (compared to the model group), its deep repair effect on the gastric mucosal microenvironment was still inferior to that of the Bianquejun 19 lysis supernatant group. Antibiotic treatment mainly relies on passively alleviating inflammation by reducing bacterial load, lacking an active mechanism for directly regulating tissue remodeling; therefore, it is slightly lagging in restoring the regularity of collagen fiber arrangement and the integrity of the mucosal barrier. In contrast, Bianque Jun 19 (especially the lysate supernatant) not only effectively eliminates bacteria, but also significantly promotes the benign remodeling of the extracellular matrix, restoring the gastric mucosa structure to a near-physiological state, demonstrating its superior "bacterial elimination + repair" dual advantages over simple antibiotic treatment.

[0126] The preferred embodiments of the present invention have been described in detail above; however, the present invention is not limited thereto. Within the scope of the inventive concept, various simple modifications can be made to the technical solutions of the present invention, including combining the various technical features in any other suitable manner. These simple modifications and combinations should also be considered as the content disclosed in the present invention and are all within the protection scope of the present invention.

Claims

1. A strain of Bifidobacterium longum subsp. ( Bifidobacterium longum subsp. longum ), characterized in that, The preservation number of this subspecies of Bifidobacterium longum is CGMCC No. 34431.

2. A microbial agent, characterized in that, The bacterial agent contains the long subsp. bifidobacterium as described in claim 1 and / or the metabolites of the long subsp. bifidobacterium as described in claim 1.

3. The microbial agent according to claim 2, wherein, The metabolites include intracellular metabolites and / or extracellular metabolites.

4. A pharmaceutical composition, characterized in that, The active ingredient of the pharmaceutical composition includes the *Bifidobacterium longum* subsp. as described in claim 1, or the bacterial agent as described in claim 2 or 3.

5. The use of the *Bifidobacterium longum* subsp. as described in claim 1, or the bacterial agent as described in claim 2 or 3, or the pharmaceutical composition as described in claim 4, in the preparation of a medicament for the prevention and / or treatment of diseases or symptoms caused by *Helicobacter pylori* infection.

6. The application according to claim 5, wherein, The disease or condition mentioned includes damage to the digestive tract mucosa caused by Helicobacter pylori infection.

7. A method for inhibiting the proliferation of Helicobacter pylori in vitro, characterized in that, The method includes contacting the long subsp. Bifidobacterium longum of claim 1, or the bacterial agent of claim 2 or 3, or the pharmaceutical composition of claim 4 with Helicobacter pylori cultured in vitro.

8. A method for inhibiting the colonization of Helicobacter pylori in in vitro cultures, characterized in that, The method involves contacting the in vitro culture with the *Bifidobacterium longum* subsp. *longum* as described in claim 1, or the bacterial agent as described in claim 2 or 3, or the pharmaceutical composition as described in claim 4, thereby inhibiting the colonization of *Helicobacter pylori* in the in vitro culture.

Citation Information

Patent Citations

  • Application of bifidobacterium animalis A6 in preparation of health-care product

    CN111135197A

  • Application of bifidobacterium bifidum B11 in preparation of product for inhibiting helicobacter pylori and repairing gastric mucosal barrier

    CN114652753A

  • Animal bifidobacterium subsp. Lactis ATM-209 for inhibiting helicobacter pylori and application thereof

    CN116622572A

  • Probiotic agent for improving gastric cancerous lesions and application thereof

    CN116650538A

  • Bifidobacterium longum subsp. Longum for improving exercise ability and application thereof

    CN116656534A